HappyLibrarian,
That name DCVax-Lung came out supposedly by accident for the original combo trial with BMY on the trial registry as I recall and I figured it might be an upgrade of some sort. Supposedly the Lung name was meant to be L for lysate but was printed up as Lung instead. Not a really big deal but I took it as a hint because I believe improvements are always in the works outside of the Phase 3 L trial and at the right time those improvements will be made known. That’s the beauty of this tech, it keeps getting better over time as activation/maturation improves and other processes, adjuvants and combos, when needed, get moved into position without drawing unwanted attention, to reach a larger and more diverse patient population. Getting positioned to take advantage of new guidance and programs with all that has been learned will propel all future applications forward at warp speed compared to past NWBO speed and this set up has all been happening behind the scenes because NWBO has remained silent about their strategy and advances with the science making it much more difficult for others to catch up. They have left clues and a deep dive into the science reveals others that they would want to be moving towards without drawing attention. One day in the not too distant future I believe you will be very pleasantly surprised, or maybe not, that NWBO’s “tardiness” was really “preparedness” for the many next steps. Best wishes.
AI
Market Data 
Markets 
